Celldex Therapeutics Q2 EPS $(0.54) Beats $(0.60) Estimate, Sales $2.50M Beat $820.43K Estimate
Portfolio Pulse from Benzinga Newsdesk
Celldex Therapeutics (NASDAQ:CLDX) reported better-than-expected Q2 results with an EPS of $(0.54) beating the $(0.60) estimate and sales of $2.50M surpassing the $820.43K estimate. This marks significant improvements over the same period last year.
August 08, 2024 | 9:08 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Celldex Therapeutics reported Q2 EPS of $(0.54), beating the $(0.60) estimate, and sales of $2.50M, significantly surpassing the $820.43K estimate. This indicates strong performance and potential positive market reaction.
The better-than-expected EPS and sales figures indicate strong operational performance. The significant year-over-year improvements suggest positive momentum, likely leading to a short-term increase in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100